Summary CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values: 20.0 U ml-'), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer patients. The aim of the present prospective study was to identify any relationship between pre-treatment serum CA 242 level and different features of lung cancer including prognosis. Serum CA 242 was measured using the delayed europium lanthanide fluoroimmunometric assay. Sensitivity and specificity were 28.5% and 95.6% respectively. Its level was significantly lower in squamous cell carcinoma in comparison with nonsquamous histologies (adenocarcinoma and large cell carcinoma). The CA 242 level was higher in metastatic disease (median: 15.3 U ml-') in comparison with non-metastatic (median: 7.9 U ml-'; Mann Whitney U test; P<0.003), and increased significantly from stage I to stage IV. In 50 patients who underwent chemotherapy, the serum CA 242 level was higher in non-responder patients when compared with responders (median: 16.8 U ml -' and 9.5 U ml-' respectively; Mann Whitney; P <0.02). Univariate analysis of the entire population showed serum CA 242 levels were not related to survival. However, patients with unresectable non-small cell lung cancer and elevated CA 242 level proved to have a significantly shorter survival than those with a CA 242 <20 U ml-'. In Cox's model analysis, stage of the disease and performance status were the only significant determinants of survival. We conclude that a high level of serum CA 242 (1) is significantly related to the stage of disease, (2) predictive of no response to chemotherapy but seems to add weak prognostic information to stage of disease and performance status, the main prognostic determinants of non-small cell lung cancer.
Lung cancer is the leading cause of cancer mortality for men and its incidence is increasing in women (Stjernsward et al., 1988) . The WHO pathologic description of malignant tumours classifies lung cancers into four groups (World Health Organization, 1982) : Small cell lung cancer (SCLC), squamous cell carcinoma, primary adenocarcinoma and large cell carcinoma. Small cell lung cancer has neuroendocrine properties which confer on this tumour specific biological and clinical features. From a prognostic and therapeutic point of view, squamous cell carcinomas, adenocarcinomas and large cell carcinomas are pooled in a non-small cell lung cancer (NSCLC) group (Mulshine et al., 1986) .
Serum carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) have been extensively studied with regard to sensitivity, specificity and applicability in the management of lung cancer (Muller et al., 1985; Salvati et al., 1985; Buccheri et al., 1986; Buccheri et al., 1987) . Both sensitivity and specificity of TPA are higher than those of serum CEA, and patients with an elevated serum TPA level have a worse prognosis on univariate analysis. Serum neuron specific enolase (NSE), a neuroendocrine marker of considerable interest in the management of SCLC (Jorgensen et al., 1989) , has been proposed as a marker of chemosensitivity for NSCLC (Carney et al., 1988) ; however, only 15% of NSCLC patients present an elevated serum NSE level at time of diagnosis (Ariyoshi et al., 1986) . Thus, new tumour markers are needed to help the management of NSCLC. Carbohydrate antigens might be putative markers inasmuch as they are expressed following neoplastic transformation of the respiratory epithelium (Tockman et al., 1992) .
CA 242 is a novel mucin related marker which detects an epitope on a protein captured by an anti-CA 50 monoclonal antibody (Nilsson et al., 1988; Haglund et al., 1989; Nilsson et al., 1992; Pasanen et al., 1992) . In a previous trial, CA 50 has been shown to be raised in 55% of NSCLC (Cooper, 1991) . The aim of the present prospective study was to identify any relationship between pre-treatment serum CA 242 level and different features of lung cancer including chemosensitivity and prognosis.
Patients and methods

Patients
One hundred and two consecutive NSCLC patients referred to the Montpellier University Hospital between February 1990 and July 1991 were prospectively entered in the study (Table I ). All patients had pathologically confirmed NSCLC. (Sobin et al., 1987) and the American Thoracic Society map of regional pulmonary nodes (Tisi et al., 1982) ( Table I) Biochemical measurements A blood sample was taken from each patient at presentation, the serum separated and stored at -800C until tested. Serum CA 242 and CEA were both measured using the delayed europium lanthanide fluoroimmunometric assay (DELFIA, Pharmacia Diagnostics AB, Uppsala, Sweden). Total lactate dehydrogenase (LDH) assays were done following the Deusch Chemical Society recommendations by measuring its activity using pyruvate as a substrate (Bio-Merieux, France).
The upper limits of normal values were as follows: CEA: 5.0 ng ml'; CA 242: 20.0 U ml' (Nilsson et al., 1988; Haglund et al., 1989; Nilsson et al., 1992) ; LDH: 330 U l-; Alkaline phosphatase: 220 U/1-'; leukocytes: 8,000 il-1. The lower limits of normal values were 32 g 1I for albumin and 135 mmol 1' for serum sodium.
All sera samples were assayed blind of clinical information.
Statistics
Receiver Operating Characteristic (ROC) curve was constructed in order to analyse the relationship between sensitivity and specificity and area under the ROC curve was calculated (Beck & Shultz, 1986 (Kaplan & Meier, 1958) . Single variable survival analyses were done by means of Wilcoxon and log-rank tests and multivariate regression was done with the Cox's model (Cox, 1972) . There were 13 variables in the model: Serum CA 242 was examined as normal (< 20 U ml-') or elevated (>20 U ml-') as were the other biological variables (CEA, significantly shorter overall survival than those with a normal level (Wilcoxon, P = 0.08; log rank, P = 0.14; Figure 3 ). However, patients with unresectable NSCLC and elevated CA 242 had a significantly shorter survival than those with a CA 242 under cut-off value (median survival 163 and 242 days respectively; log rank test; P = 0.03; Figure 4 ). Separate survival analyses showed a significant effect of the stage of the disease, a 2 or 3 performance status, presence of weight loss, low serum albumin and elevated serum LDH (Table  IV) . No difference in overall survival was seen when histological type, age, sex, serum sodium, alkaline phosphatase and serum CEA level were considered. With Cox's model analysis, stage-grouping of the disease (coeffiicient = 0.71; P = 0.0019) and performance status (coefficient = 0.54; P = 0.005) were the only significant determinants of survival. Other variables including pre-treatment serum CA 242 and CEA level were removed from Cox's model.
Discussion
The results of this study suggest that serum CA 242 level has a greater sensitivity in non-squamous histologies than in SQC and that its distribution in NSCLC is significantly related to stage of the disease. Interestingly, the distribution of serum CA 242 differs according to clinical response to chemotherapy inasmuch as responder patients had a significantly lower serum level of this marker when compared with patients in whom the disease was not controlled. However, the level of CA 242 seems to be only a weak prognostic factor as stage of disease and performance status remain the only two prognostic determinants in multivariate analysis.
Surgery is the main treatment of low stage NSCLC (Naruke et al., 1988) . For the remaining patients, NSCLC is considered as a systemic disease, sometimes at the microscopic stage, rather than clinically evident (Gregor, 1991) . Theoretically, such a systemic disease requires a systemic treatment whether given alone or in a combined modality treatment including radiation therapy to improve local control. However, sensitivity of NSCLC to cytotoxic agents is low and survival benefit for unresectable patients obtained by chemotherapy, although well demonstrated, remains poor bar = median value; columns = inter- (Rapp et al., 1988) . Thus, the treatment of locally advanced or metastatic NSCLC is still a subject of controversy (Gregor, 1991 (Buccheri et al., 1987) . In an early study involving 131 patients with lung cancer a high level of serum CEA was predictive of poor prognosis in the unresectable group (Dent et al., 1978) . In a more recent study of 98 patients the value of CEA as a prognostic marker was confirmed (Buccheri et al., 1986) but another study published by the same group 1 year later with a larger number of patients failed to confirm this (Buccheri et al., 1987) . It may be underlined, that, in all these studies, the value of CEA as a prognostic marker was analysed in populations of patients having lung cancer of any histology (i.e. pooling SCLC and NSCLC). This perturbs the interpretation of the results because it is now demonstrated that CEA level has a prognostic influence on patients with SCLC (Gronowitz et al., 1990) . Moreover, only univariate analyses of survival have been done and, inasmuch as CEA is related to disease extent, its value as an independent prognostic variable is questionable. This is emphasised by the results of another study of 10 serum proteins measured in 215 lung cancer patients (Muller et al., 1985) . CEA was not statistically related to survival whichever operable or inoperable patients were considered, as is also the case in our study.
In our study we tested a novel tumour associated antigen, CA242 in NSCLC. This mucin-related marker detects an epitope on a protein captured by an anti-CA 50 monoclonal antibody (Nilsson et al., 1988; Haglund et al., 1989) . This tumour marker has been studied extensively in pancreatic carcinoma (Pasanen et al., 1992) and in other gastro-intestinal cancers (Nilsson et al., 1992 CA 242 seems to be a more promising tumour marker in the unresectable group. We studied a non-small cell lung cancer population with a high proportion of locally advanced or metastatic diseases, It has been extensively published that these patients proved to have a short survival (Mulshine et al., 1986; Gregor, 1991; Rapp et al., 1988) ; therefore, chemotherapy or chemotherapy/radiotherapy combination may be proposed (Gregor, 1991; Rapp et al., 1988 
